Compound Evidence File
#EC-2026-0292
Tesamorelin 11mg + Ipamorelin 6mg Blend
Filed under Peptides. The bureau holds 165 laboratory returns for this compound from 54 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
54 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 7 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 9.9 | 10.0 | 28 Feb 2026 | 15 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 6 Mar 2026 | 3 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 9.9 | 10.0 | 2 Dec 2025 | 2 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 9.9 | 10.0 | 9 Feb 2026 | 17 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 10.0 | 9.9 | 10.0 | 17 Mar 2026 | 13 Aug 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 10.0 | 10.0 | 25 Nov 2025 | 12 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 10 May 2026 | 17 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 22 Feb 2026 | 17 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 10.0 | 10.0 | 17 Apr 2026 | 8 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Feb 2026 | 10 Aug 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 12 May 2026 | 16 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Apr 2026 | 15 Aug 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 1 Mar 2026 | 3 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 13 Mar 2026 | 3 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 21 Nov 2025 | 18 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Mar 2026 | 25 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 21 Apr 2026 | 25 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 10.0 | 4 May 2026 | 7 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 9.9 | 9.9 | 10.0 | 7 Jun 2026 | 19 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 9.9 | 11 Nov 2025 | 3 Apr 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 9.9 | 25 May 2026 | 15 Jun 2026 |
| Shanxi Qianyecao Biotech QYCCASE #VI-2026-0189 | X | 1 | 9.6 | 9.6 | 9.6 | 16 Mar 2025 | 16 Mar 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 8.9 | 8.2 | 9.4 | 23 May 2026 | 23 May 2026 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 2 | 8.9 | 8.7 | 9.2 | 6 May 2025 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.8 | 7.1 | 10.0 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 4 | 8.7 | 7.2 | 10.0 | 23 May 2026 | 23 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 8.4 | 7.4 | 9.8 | 24 May 2026 | 24 May 2026 |
| Trusted PeptideCASE #VI-2026-0499 | X | 1 | 8.4 | 8.4 | 8.4 | 13 Feb 2025 | 13 Feb 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.2 | 6.6 | 9.2 | 21 May 2026 | 21 May 2026 |
| Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 | X | 2 | 8.2 | 6.5 | 10.0 | 13 Jun 2025 | 20 May 2026 |
| Bfflist AMOCASE #VI-2026-0678 | X | 5 | 8.1 | 6.8 | 9.1 | 14 Jan 2025 | 21 May 2026 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 7.8 | 7.8 | 7.8 | 2 Jul 2025 | 2 Jul 2025 |
| Allen Biotechnology Co ABCCASE #VI-2026-0709 | X | 3 | 7.6 | 6.0 | 8.5 | 14 Jan 2025 | 19 Jan 2026 |
| Zztai PeptideCASE #VI-2026-0192 | C | 3 | 7.3 | 5.4 | 10.0 | 9 Jun 2025 | 20 May 2026 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 6 | 7.3 | 4.8 | 9.0 | 3 Jul 2025 | 24 May 2026 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 7.1 | 7.1 | 7.1 | 11 Jun 2025 | 11 Jun 2025 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 6.8 | 6.8 | 6.8 | 13 Feb 2025 | 13 Feb 2025 |
| WllyBIOCASE #VI-2026-0470 | X | 1 | 6.8 | 6.8 | 6.8 | 7 May 2025 | 7 May 2025 |
| UtherCASE #VI-2026-0902 | X | 5 | 6.7 | 2.4 | 9.5 | 16 Mar 2025 | 21 May 2026 |
| Royal PeptidesCASE #VI-2026-0264 | X | 3 | 6.6 | 5.0 | 8.0 | 7 May 2025 | 19 Jan 2026 |
| Peptide WorldwideCASE #VI-2026-0217 | X | 1 | 6.5 | 6.5 | 6.5 | 17 Dec 2024 | 17 Dec 2024 |
| LiliPeptideCASE #VI-2026-0695 | X | 9 | 6.4 | 3.6 | 8.8 | 20 Jun 2025 | 24 May 2026 |
| Peptide CraftersCASE #VI-2026-0994 | X | 1 | 6.1 | 6.1 | 6.1 | 6 May 2025 | 6 May 2025 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | X | 1 | 5.8 | 5.8 | 5.8 | 8 Jul 2025 | 8 Jul 2025 |
| NextechLabsCASE #VI-2026-0285 | X | 2 | 5.4 | 4.8 | 6.1 | 2 Apr 2025 | 20 May 2026 |
| ZhuoYan labCASE #VI-2026-0902 | X | 2 | 5.3 | 4.7 | 5.9 | 17 Dec 2024 | 25 May 2026 |
| Amplified AminoCASE #VI-2026-0748 | X | 1 | 5.3 | 5.3 | 5.3 | 2 Jul 2025 | 2 Jul 2025 |
| Richards Biotech Simply RichardsCASE #VI-2026-0307 | X | 1 | 4.9 | 4.9 | 4.9 | 2 Apr 2025 | 2 Apr 2025 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 3.2 | 3.2 | 3.2 | 28 Mar 2025 | 28 Mar 2025 |
| Simple PeptideCASE #VI-2026-0782 | X | 1 | 3.0 | 3.0 | 3.0 | 21 May 2025 | 21 May 2025 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 1 | 3.0 | 3.0 | 3.0 | 3 Jul 2025 | 3 Jul 2025 |
| Lejian Biotech PeptideCASE #VI-2026-0746 | X | 1 | 0.5 | 0.5 | 0.5 | 21 May 2025 | 21 May 2025 |
Open any subject to view the batch-level evidence for Tesamorelin 11mg + Ipamorelin 6mg Blend alone.